| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Revenue from cell therapy products was US$20.6 million, up from US$12.9 million in the previous quarter ended June 30, 2025, an...
 
																	
 
																	
 
																	
 
																	 
																	
 
																	
 
																	Mesoblast Limited (NASDAQ:MESO) shares are trading higher on Friday after the company announced that Ryoncil received a J-Code ...
